Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | AURKA | O14965 | 6/20 | 0.43 |
| ▸ | TEK | Q02763 | 6/20 | 0.43 |
| ▸ | MET | P08581 | 5/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286687 | 0.78 | PTPN1 (0.57) | PTPN1CDC25BNR4A1NR4A2NR4A3 | |
| SCHEMBL344419 | 0.78 | PTPN11 (0.61) | PTPN1MTNR1AKMT2ACYP2C9 | |
| SCHEMBL2510203 | 0.78 | CDC25B (0.64) | PTPN1CDC25BKDRAURKATEK | |
| SCHEMBL31613816 | 0.78 | CDC25B (0.64) | PTPN1CDC25BKDRAURKATEK | |
| SCHEMBL1029366 | 0.78 | KDM4E (0.58) | CTNNB1KDM4E | |
| SCHEMBL6562624 | 0.77 | PTPN7 (0.64) | PTPN1CDC25BNR4A1NR4A2NR4A3 | |
| SCHEMBL9001552 | 0.77 | PTPN11 (0.63) | PTPN1 | |
| SCHEMBL2880021 | 0.76 | RARG (0.50) | CTNNB1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2868546 | 0.76 | KMT2A (0.61) | NR4A1NR4A2NR4A3KMT2ANR1H4 | |
| SCHEMBL2875045 | 0.75 | KDM4E (0.54) | CTNNB1MEN1KMT2ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | disclosed |
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | disclosed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1572629-A1 | COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052840-A1 | COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | MITF, AHR, PAH | PTPN1 1515/4885CDC25B 2543/4885KDR 1242/4885 |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PTPN1 802/4885CDC25B 3184/4885KDR 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.